Axsome Therapeutics, Inc. (AXSM) Financials
Annual revenue, profitability and per-share results for Axsome Therapeutics, Inc., as reported in SEC filings.
Revenue • FY2025
$638.5M
▲ 65.5%YoY
Net income • FY2025
-$183.17M
▲ 36.2%YoY
Gross margin • FY2025
92.6%
Diluted EPS • FY2025
-$3.68
▲ 38.6%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $638.5M | -$183.17M | $591.02M | -$3.68 | -$93.89M | -26.1% | +65.5% |
| FY2024 | $385.69M | -$287.22M | $352.39M | -$5.99 | -$128.68M | -72.7% | +42.5% |
| FY2023 | $270.6M | -$239.24M | $244.53M | -$5.27 | -$145.66M | -85.7% | +440.8% |
| FY2022 | $50.04M | -$187.13M | $44.84M | -$4.60 | -$117.21M | -359.3% | — |
Figures as reported in Axsome Therapeutics, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a AXSM filing.
Get an email when AXSM files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.